Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

438 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Multibiomarker Acro-TIME Score Predicts fg-SRLs Response: Preliminary Results of a Retrospective Acromegaly Cohort.
Chiloiro S, Moroni R, Giampietro A, Angelini F, Gessi M, Lauretti L, Mattogno PP, Calandrelli R, Tartaglione T, Carlino A, Gaudino S, Olivi A, Rindi G, De Marinis L, Pontecorvi A, Doglietto F, Bianchi A. Chiloiro S, et al. Among authors: pontecorvi a. J Clin Endocrinol Metab. 2024 Apr 19;109(5):1341-1350. doi: 10.1210/clinem/dgad673. J Clin Endocrinol Metab. 2024. PMID: 37975821
Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response.
Chiloiro S, Giampietro A, Mirra F, Donfrancesco F, Tartaglione T, Mattogno PP, Angelini F, Liverana L, Gessi M, Carmelo A, Rindi G, Giustina A, Fleseriu M, Pontecorvi A, De Marinis L, Bianchi A. Chiloiro S, et al. Among authors: pontecorvi a. Eur J Endocrinol. 2021 Feb;184(2):217-229. doi: 10.1530/EJE-20-0767. Eur J Endocrinol. 2021. PMID: 33136550
Second line treatment of acromegaly: Pasireotide or Pegvisomant?
Chiloiro S, Bianchi A, Giampietro A, Pontecorvi A, Raverot G, Marinis L. Chiloiro S, et al. Among authors: pontecorvi a. Best Pract Res Clin Endocrinol Metab. 2022 Dec;36(6):101684. doi: 10.1016/j.beem.2022.101684. Epub 2022 Jul 16. Best Pract Res Clin Endocrinol Metab. 2022. PMID: 35931640 Review.
Cholecalciferol Use Is Associated With a Decreased Risk of Incident Morphometric Vertebral Fractures in Acromegaly.
Chiloiro S, Frara S, Gagliardi I, Bianchi A, Giampietro A, Medici M, Allora A, di Filippo L, Ambrosio MR, Pontecorvi A, Zatelli MC, De Marinis L, Giustina A. Chiloiro S, et al. Among authors: pontecorvi a. J Clin Endocrinol Metab. 2023 Dec 21;109(1):e58-e68. doi: 10.1210/clinem/dgad493. J Clin Endocrinol Metab. 2023. PMID: 37606222 Free PMC article.
Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas.
Fusco A, Zatelli MC, Bianchi A, Cimino V, Tilaro L, Veltri F, Angelini F, Lauriola L, Vellone V, Doglietto F, Ambrosio MR, Maira G, Giustina A, degli Uberti EC, Pontecorvi A, De Marinis L. Fusco A, et al. Among authors: pontecorvi a. J Clin Endocrinol Metab. 2008 Jul;93(7):2746-50. doi: 10.1210/jc.2008-0126. Epub 2008 May 6. J Clin Endocrinol Metab. 2008. PMID: 18460561
Prevalence of vertebral fractures in men with acromegaly.
Mazziotti G, Bianchi A, Bonadonna S, Cimino V, Patelli I, Fusco A, Pontecorvi A, De Marinis L, Giustina A. Mazziotti G, et al. Among authors: pontecorvi a. J Clin Endocrinol Metab. 2008 Dec;93(12):4649-55. doi: 10.1210/jc.2008-0791. Epub 2008 Sep 30. J Clin Endocrinol Metab. 2008. PMID: 18827004
438 results